Beximco Pharmaceuticals Limited (DSE: BXPHARMA)

Market Cap	39.79B
Revenue (ttm)	44.95B
Net Income (ttm)	5.96B
Shares Out	446.11M
EPS (ttm)	13.36
PE Ratio	6.68
Forward PE	5.91
Dividend	4.00 (4.48%)
Ex-Dividend Date	Nov 26, 2024

Volume	1,845,039
Open	85.50
Previous Close	84.50
Day's Range	85.40 - 89.50
52-Week Range	64.20 - 146.20
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 4, 2024

About Beximco Pharmaceuticals

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to ...

• Industry: Pharmaceutical Preparations
• Founded: 1976
• Employees: 5,700
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: BXPHARMA

Financial Performance

In 2024, Beximco Pharmaceuticals's revenue was 44.39 billion, an increase of 13.05% compared to the previous year's 39.27 billion. Earnings were 5.83 billion, an increase of 26.34%.